logo
episode-header-image
May 2025
10m 53s

WARRIOR Trial: Outcomes to Reduce Events...

AMERICAN COLLEGE OF CARDIOLOGY
About this episode

Funded by the Congressionally Directed Medical Research Programs (CDMRP) of the Department of Defense, the WARRIOR (Women's IschemiA TRial to Reduce events In non-ObstRuctive CAD) Trial addresses the urgent need for evidence-based care in a growing population of patients—particularly women—experiencing ischemia without obstructive coronary artery disease (INOCA). 

 

This clinical strategy trial compares optimal medical therapy with usual care in women with angina but no significant coronary blockages. In this episode, Drs. Nanette Kass Wenger and Noel Bairey Merz discuss the trial’s design, enrollment progress, follow-up strategies, and the primary and secondary outcomes that could reshape cardiovascular care for women. 

Subscribe on Apple Podcasts || Subscribe to ACCEL 

Up next
Oct 7
ODYSSEY-HCM: Mavacamten in nHCM
The ODYSSEY-HCM trial found that mavacamten did not significantly improve exercise capacity or patient-reported outcomes in individuals with symptomatic nonobstructive hypertrophic cardiomyopathy. Safety concerns emerged, including more frequent reductions in ejection fraction an ... Show More
12m 10s
Sep 30
DAN-RSV: RSVpreF Vaccine for Preventing Cardiorespiratory Hospitalizations
The DAN-RSV trial is one of the largest individually randomized studies ever conducted, enrolling over 131,000 participants aged 60 and older to evaluate the effectiveness of the RSVpreF vaccine. Using a pragmatic design with electronic consent and national health registry data, ... Show More
9m 58s
Sep 23
The Role of Prevention During and After Reproduction
Adverse pregnancy outcomes (APOs), affecting up to 20% of pregnancies, serve as early indicators of a woman’s future cardiovascular risk and should be treated as critical markers in preventive care. Pregnancy offers a unique opportunity—a “window”—to identify and address cardiova ... Show More
13m 24s
Recommended Episodes
Feb 2025
LifeBTK Trial: Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease
In this episode of Audible Bleeding, Jamila, Anh, and Naveed discuss the LifeBTK Trial with Principal Investigator Dr. Brian DeRubertis, where we discuss the new Abbott Esprit everolimus-eluting resorbable scaffold for the below-knee popliteal space. Guest: Dr. DeRubertis, is the ... Show More
47m 12s
Jun 2025
#180 Beta-Blockers & REDUCE-AMI Trial: Beyond Journal Club Segment with NEJM Group
How much do beta blockers help after a heart attack, even when the heart’s pumping well? In this episode, we revisit the origins of beta blockers in post-MI care, examine how evidence evolved, and explore the REDUCE-AMI trial, which questions whether beta blockers are still neede ... Show More
26m 41s
Feb 2025
PTJ Author Interview: Randomized Clinical Trials and Real-World Practice
In this episode of the PTJ Podcast, Editor-in-Chief Steven George, PT, PhD, FAPTA, talks with Alexander Garbin, PT, DPT, PhD, and Jennifer Stevens-Lapsley, PT, PhD, FAPTA, about their recently published companion papers, which evaluated the effectiveness of a progressive multicom ... Show More
24m 12s
Sep 8
Reframing Cardiovascular Care | JACC This Week
In this episode, Dr. Harlan Krumholz introduces the September 16, 2025 issue of JACC, which features studies that challenge conventional clinical thinking, including a detailed ECMO physiology study showing that higher ECMO flow does not uniformly raise pulmonary capillary wedge ... Show More
13m 24s
Nov 2024
JACC Journals at AHA | JACC | AHA 2024
Join Harlan Krumholz, editor-in-chief of JACC, as he highlights groundbreaking cardiovascular science presented at this year's American Heart Association Scientific Sessions. From obesity-related heart failure to innovations in stroke prevention and disparities in care, this epis ... Show More
3m 40s
Sep 15
AI, Polygenic Risk Scores, and Antithrombotic Therapy | JACC This Week
In this episode, Editor-in-Chief Harlan Krumholz explores the evolving landscape of cardiovascular medicine, beginning with a call for responsible stewardship of artificial intelligence. Highlights include a major registry study on percutaneous aspiration for right-sided endocard ... Show More
9m 54s
Sep 26
Sep 26 2025 This Week in Cardiology
A bold trial in valvular heart disease, a CV prevention trial whose message is humility, VTE dogma challenged, more news on oral GLP-1 agonists, and a few public service announcements are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for ... Show More
22m 50s
Oct 2024
#458 HFrEF: Heart Failure with Reduced Ejection Fraction
Kittleson Rules Outpatient Heart Failure Volume 1 Provide superb outpatient care for your patients with HFrEF. Identify underlying causes of heart failure and titrate medications with ease. Dr Michelle Kittleson @MKittlesonMD (Cedars Sinai) breaks down the nuances of treating thi ... Show More
1h 4m
Jan 2025
409. Journal Club: The ARREST-AF Trial with Drs. Prashanthan Sanders and Mehak Dhande
Join CardioNerds EP Council Chair Dr. Naima Maqsood and Episode Lead Dr. Jeanne De Lavallaz as they discuss the results of the ARREST-AF Trial with expert faculty Dr. Prashanthan Sanders and Dr. Mehak Dhande. Audio editing by CardioNerds intern Bhavya Shah. The ARREST-AF trial en ... Show More
36m 4s
Jul 8
How to Prevent Heart Disease with Mitochondria, Muscle, and the Endothelial Glycocalyx | Dr. Michael Twyman
Did you know every 40 seconds someone in the U.S. has a heart attack—and 1 in 5 never even see it coming? This week, I am joined by preventive cardiologist Dr. Michael Twyman as we discuss cutting-edge diagnostics, the endothelial glycocalyx, nitric oxide biology, and why muscle ... Show More
1h 43m